This is a contract award for Rasagiline tablets in 0. 5 mg and 1 mg strengths, packaged in 30-count bottles. The contract includes a base year and four option years. The estimated total value for the 5-year period is $6,637,357. 21. The products will be manufactured by Carnegie Pharmaceuticals, LLC, located at 600 Delran Parkway, Delran, New Jersey **** State Medical Supply, Inc. is also involved in the packaging process. The contract incorporates by reference various Federal Acquisition Regulation (FAR) clauses. Specific details regarding delivery, payment, and warranty are not explicitly detailed in this excerpt but are governed by the incorporated FAR clauses.
The delivery deadline is not explicitly stated in this document, but it is governed by the incorporated Federal Acquisition Regulation (FAR) clauses.
The payment terms are not explicitly stated in this document, but they are governed by the incorporated Federal Acquisition Regulation (FAR) clauses, including provisions for electronic funds transfers.
The warranty terms are not explicitly stated in this document, but they are governed by the incorporated Federal Acquisition Regulation (FAR) clauses.
The award criterion is not explicitly stated in this document, but the contract award is based on an offer from Golden State Medical Supply, Inc. dated 10/08/2025, with a final proposal revision on 02/18/2026.
The qualification requirements are not explicitly detailed in this excerpt, but the contract is awarded to Golden State Medical Supply, Inc. based on their offer and proposal revision.
The penalties are not explicitly stated in this document, but they are governed by the incorporated Federal Acquisition Regulation (FAR) clauses, such as FAR ****, Liquidated Damages-Subcontracting Plan.
The challenge deadline is not explicitly stated in this document, but FAR ****, Protest after Award, is incorporated by reference.
The total estimated value for this contract over 5 years is $6,637,****.